A ‘designer’ manganese-peptide antioxidant of the world’s toughest bacterium, combined with radiation, have shown to be successful in the development of a vaccine to counter Venezuelan Equine Encephalitis Virus (VEEV), a biothreat agent, and Chikungunya virus, a mosquito-borne illness causing severe outbreaks around the world, according to a study “Deinococcus Mn2+-Peptide Complex: A Novel Approach to Alphavirus Vaccine Development,” published online May 30 in the journal, Vaccine, published by Elsevier, http://www.sciencedirect.com/ science/article/pii/ S0264410X17306242.
Effective vaccines depend upon the human immune system recognizing a biological structure that is similar to that of a disease-causing organism. A manganese-peptide antioxidant complex of Deinococcus, developed by Uniformed Services University of the Health Sciences (USU) pathology professor Dr. Michael J. Daly and his team, has the remarkable property of protecting proteins from ionizing radiation damage but not protecting the genetic material (DNA or RNA) in viruses and bacteria. Using D. radiodurans, listed in the Guinness Book of World Records as “the world’s toughest bacterium” and which can withstand 3,000 times the levels of gamma radiation that human cells can, Daly found that a disease-causing organism (pathogen) can be exposed to gamma radiation in the presence of a Deinococcus Mn complex, and rendered non-replicative (killed) by overwhelming genetic damage, but still maintain the shape of key surface proteins needed to mount a highly protective immune response. This approach was successfully implemented on viruses for the first time by scientists in the USU lab of the late Dr. Radha K. Maheshwari to produce vaccines against VEEV and Chikungunya virus.
This approach offers a simple, rapid, cost effective and potentially universal inactivation strategy that can be applied to any pathogen requiring immediate attention, for example, Ebola and Zika viruses.
“Application of this methodology has the potential to revolutionize all future vaccine development” says Dr. Paridhi Gupta, a scientist in the Maheshwari laboratory, and the study’s co-lead author.
Learn more: New Vaccine Strategy Identified for Explosive Emerging Diseases
[osd_subscribe categories=’vaccines’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “VACCINES’]
The Latest on: Vaccine development
[google_news title=”” keyword=”vaccine development” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Our new vaccine could protect against coronaviruses that haven’t even emerged yet – new study
The rapid development of vaccines that protect against COVID was a remarkable scientific achievement that saved millions of lives. The vaccines have demonstrated substantial success in reducing death ...
- Infectious Vaccine Collaboration, Development, Research and Licensing Deals Trends Report 2024 with Directory of 522 Agreements Signed Since 2019
The "Infectious Vaccine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Infectious Vaccine Collaboration and Licensing Deals provides a ...
- How mRNA vaccines could be personalized cancer cures
An expanding pipeline of vaccines is giving patients new hope against some of the deadliest cancers, by training the body's immune system to attack malignancies. Why it matters: This personalized ...
- Vaccine Development For COVID Viruses Currently And In The Future
There is a growing interest among scientists in developing a vaccine to combat strains of the COVID virus SARS-CoV-2 that have yet to emerge. In mouse studies, the efforts of a British team at the ...
- Global Vaccines Market Set to Skyrocket to USD 80.8 Billion by 2033: FMI Positioned for Growth
The global vaccines market is poised for unprecedented growth, with a projected Compound Annual Growth Rate (CAGR) of 6.6%, catapulting it to an impressive USD 80.8 billion by 2033. This surge marks a ...
via Google News and Bing News